Potential therapeutic biomolecules of hymenopteran venom against SARS-CoV-2 from Egyptian patients

被引:0
作者
Abd El Maksoud, Eman A. [1 ]
Rady, Magda H. [2 ]
Mahmoud, Ahmed Gad Taha [3 ]
Hamza, Dalia [4 ]
Seadawy, Mohamed G. [5 ,6 ]
Essa, Eman. E. [2 ,6 ]
机构
[1] Armed Forces Labs Med Res, El Khalifa El Maamoun,Mansheya El Bakry, Heliopolis, Cairo Governora, Egypt
[2] Ain Shams Univ, Fac Sci, Entomol Dept, Cairo 11566, Egypt
[3] Armed Forces Labs Med Res, Microbiol Dept, El Khalifa El Maamoun,Mansheya El Bakry, Heliopolis, Cairo Governora, Egypt
[4] Cairo Univ, Fac Vet Med, Zoonoses Dept, Giza, Egypt
[5] Egypt Army, Biol Prevent Dept, Chem Warfare, Cairo, Egypt
[6] Ain Shams Univ, Fac Sci, Entomol Dept, Cairo, Egypt
来源
SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期
关键词
PHOSPHOLIPASE A(2); MELITTIN; ASSAY; MASTOPARAN; BEE;
D O I
10.1038/s41598-024-65038-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The therapeutic potential of insect-derived bioactive molecules as anti-SARS-CoV-2 agents has shown promising results. Hymenopteran venoms, notably from Apis mellifera (honeybee) and Vespa orientalis (oriental wasp), were examined for the first time in an in vitro setting for their potential anti-COVID-19 activity. This assessment utilized an immunodiagnostic system to detect the SARS-CoV-2 nucleocapsid antigen titer reduction. Further analyses, including cytotoxicity assays, plaque reduction assays, and in silico docking-based screening, were performed to evaluate the efficacy of the most potent venom. Results indicated that bee and wasp venoms contain bioactive molecules with potential therapeutic effects against SARS-CoV-2.Nevertheless, the wasp venom exhibited superior efficacy compared to bee venom, achieving a 90% maximal (EC90) concentration effect of antigen depletion at 0.184 mg/mL, in contrast to 2.23 mg/mL for bee venom. The cytotoxicity of the wasp venom was assessed on Vero E6 cells 48 h post-treatment using the MTT assay. The CC 50 of the cell growth was 0.16617 mg/mL for Vero E6 cells. The plaque reduction assay of wasp venom revealed 50% inhibition (IC50) at a 0.208 mg/mL concentration. The viral count at 50% inhibition was 2.5 x 104 PFU/mL compared to the initial viral count of 5 x 104 PFU/mL. In silico data for the wasp venom revealed a strong attraction to binding sites on the ACE2 protein, indicating ideal interactions. This substantiates the potential of wasp venom as a promising viral inhibitor against SARS-CoV-2, suggesting its consideration as a prospective natural preventive and curative antiviral drug. In conclusion, hymenopteran venoms, particularly wasp venom, hold promise as a source of potential therapeutic biomolecules against SARS-CoV-2. More research and clinical trials are needed to evaluate these results and investigate their potential for translation into innovative antiviral therapies.
引用
收藏
页数:12
相关论文
共 41 条
[1]   Wasp Venom Biochemical Components and Their Potential in Biological Applications and Nanotechnological Interventions [J].
Abd El-Wahed, Aida ;
Yosri, Nermeen ;
Sakr, Hanem H. ;
Du, Ming ;
Algethami, Ahmed F. M. ;
Zhao, Chao ;
Abdelazeem, Ahmed H. ;
Tahir, Haroon Elrasheid ;
Masry, Saad H. D. ;
Abdel-Daim, Mohamed M. ;
Musharraf, Syed Ghulam ;
El-Garawani, Islam ;
Kai, Guoyin ;
Al Naggar, Yahya ;
Khalifa, Shaden A. M. ;
El-Seedi, Hesham R. .
TOXINS, 2021, 13 (03)
[2]  
Abdelfattah EA., 2021, J. Egypt. Soc. Parasitol, V51, P533, DOI [10.21608/jesp.2021.210439, DOI 10.21608/JESP.2021.210439]
[3]   Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2; Antiviral Screening and Molecular Docking Studies [J].
Al-Rabia, Mohammed W. ;
Alhakamy, Nabil A. ;
Ahmed, Osama A. A. ;
Eljaaly, Khalid ;
Alaofi, Ahmed L. ;
Mostafa, Ahmed ;
Asfour, Hani Z. ;
Aldarmahi, Ahmed A. ;
Darwish, Khaled M. ;
Ibrahim, Tarek S. ;
Fahmy, Usama A. .
PHARMACEUTICS, 2021, 13 (03) :1-21
[4]  
Alia O., 2013, Int. J. Pharm. Sci. Rev. Res, V21, P318
[5]  
Alves RRN., 2013, Animals in Traditional Folk Medicine, DOI [10.1007/978-3-642-29026-85, DOI 10.1007/978-3-642-29026-85]
[6]  
[Anonymous], 2021, Biomed. Saf. Stand., V51, P77
[7]  
ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697
[8]   Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics [J].
Arshad, Usman ;
Pertinez, Henry ;
Box, Helen ;
Tatham, Lee ;
Rajoli, Rajith K. R. ;
Curley, Paul ;
Neary, Megan ;
Sharp, Joanne ;
Liptrott, Neill J. ;
Valentijn, Anthony ;
David, Christopher ;
Rannard, Steve P. ;
O'Neill, Paul M. ;
Aljayyoussi, Ghaith ;
Pennington, Shaun H. ;
Ward, Stephen A. ;
Hill, Andrew ;
Back, David J. ;
Khoo, Saye H. ;
Bray, Patrick G. ;
Biagini, Giancarlo A. ;
Owen, Andrew .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (04) :775-790
[9]   Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019 [J].
Burbelo, Peter D. ;
Riedo, Francis X. ;
Morishima, Chihiro ;
Rawlings, Stephen ;
Smith, Davey ;
Das, Sanchita ;
Strich, Jeffrey R. ;
Chertow, Daniel S. ;
Davey, Richard T., Jr. ;
Cohen, Jeffrey, I .
JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (02) :206-213
[10]   HEMOCIDINS DERIVED FROM HEMOGLOBIN: STRUCTURES, PROPERTIES AND PERSPECTIVES [J].
Carvalho, Larissa A. C. ;
Machini, Maria Teresa .
QUIMICA NOVA, 2013, 36 (07) :1021-1029